Please ensure Javascript is enabled for purposes of website accessibility

Baltimore company offers cancer gene testing product

Personal Genome Diagnostics Inc., of Baltimore, a provider of cancer genome analysis and testing services, announced on Thursday it is offering its CancerSelect targeted gene panel through the company’s MyPersonalGenome service. In addition to detecting gene alterations that can identify cancer progression and response to treatment, CancerSelect is the only gene panel that compares the patient’s tumor DNA with his or her normal DNA, Personal Genome Diagnostics said. This enables treatment to focus on alterations that are tumor-specific.